# Talaris Therapeutics Inc. (TALS)

Source: https://www.quantisnow.com/company/TALS
Generated: 2026-10-31T12:35:47.390Z

- Ticker: TALS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: talaristx.com

## About

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

## Latest TALS news and filings

- 2024-02-15 02:08 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-talaris-therapeutics-inc-amendment-5265810)
- 2024-02-15 01:51 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-talaris-therapeutics-inc-5265780)
- 2024-02-14 22:04 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-talaris-therapeutics-inc-amendment-5264848)
- 2024-02-14 21:57 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-talaris-therapeutics-inc-amendment-5264637)
- 2024-02-09 22:24 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-talaris-therapeutics-inc-amendment-5247322)
- 2024-02-09 21:22 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-talaris-therapeutics-inc-5246715)
- 2024-02-07 19:11 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-talaris-therapeutics-inc-amendment-5237085)
- 2024-01-31 21:26 UTC [Insider Buy] [Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)](https://www.quantisnow.com/insight/mcdade-mark-bought-3250000-worth-of-shares-100000-units-at-5220716)
- 2024-01-26 21:12 UTC [SEC Form 8-K] [Talaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/talaris-therapeutics-inc-filed-sec-form-8-k-financial-statements-and-5211087)
- 2024-01-26 21:08 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-talaris-therapeutics-inc-5211042)
- 2024-01-25 02:20 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-talaris-therapeutics-inc-5206005)
- 2024-01-24 22:10 UTC [SEC Form 8-K] [Talaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/talaris-therapeutics-inc-filed-sec-form-8-k-results-of-operations-5205436)
- 2024-01-08 14:19 UTC [SEC Form 8-K] [Talaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/talaris-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-5175591)
- 2023-12-15 21:23 UTC [SEC Form 4] [SEC Form 4 filed by Siegall Clay B](https://www.quantisnow.com/insight/sec-form-4-filed-by-siegall-clay-b-5140883)
- 2023-12-15 21:21 UTC [SEC Form 3] [SEC Form 3 filed by new insider Siegall Clay B](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-siegall-clay-b-5140867)
- 2023-12-14 13:27 UTC [SEC Form 8-K] [Talaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/talaris-therapeutics-inc-filed-sec-form-8-k-leadership-update-regulation-5137162)
- 2023-11-30 13:25 UTC [SEC Form 8-K] [Talaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/talaris-therapeutics-inc-filed-sec-form-8-k-leadership-update-5110405)
- 2023-11-20 23:15 UTC [Insider Buy] [Kulkarni Sandeep Chidambar bought $67,960 worth of shares (4,000 units at $16.99), increasing direct ownership by 0.55% to 729,735 units (SEC Form 4)](https://www.quantisnow.com/insight/kulkarni-sandeep-chidambar-bought-67960-worth-of-shares-4000-units-5096857)
- 2023-11-20 23:14 UTC [Insider Buy] [Thiara Parvinder bought $17,310 worth of shares (1,000 units at $17.31), increasing direct ownership by 1% to 83,782 units (SEC Form 4)](https://www.quantisnow.com/insight/thiara-parvinder-bought-17310-worth-of-shares-1000-units-at-5096856)
- 2023-11-06 21:30 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-talaris-therapeutics-inc-5062534)
- 2023-10-30 21:16 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-talaris-therapeutics-inc-amendment-5044893)
- 2023-10-30 20:15 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Talaris Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-talaris-therapeutics-inc-amendment-5044348)
- 2023-10-27 21:17 UTC [SEC Form 8-K] [SEC Form 8-K filed by Talaris Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-talaris-therapeutics-inc-5042350)
- 2023-10-27 21:43 UTC [Insider Buy] [Castelein Caley bought $280,584 worth of shares (20,000 units at $14.03), increasing direct ownership by 4% to 516,519 units (SEC Form 4)](https://www.quantisnow.com/insight/castelein-caley-bought-280584-worth-of-shares-20000-units-at-5042298)
- 2023-10-24 00:33 UTC [SEC Form 4] [Thiara Parvinder was granted 75,782 shares (SEC Form 4)](https://www.quantisnow.com/insight/thiara-parvinder-was-granted-75782-shares-sec-form-4-5033478)
- 2023-10-24 00:31 UTC [SEC Form 4] [Srivastava Sapna was granted 518 shares (SEC Form 4)](https://www.quantisnow.com/insight/srivastava-sapna-was-granted-518-shares-sec-form-4-5033476)
- 2023-10-24 00:30 UTC [SEC Form 4] [SEC Form 4 filed by Robinson Ryan F.](https://www.quantisnow.com/insight/sec-form-4-filed-by-robinson-ryan-f-5033475)
- 2023-10-24 00:29 UTC [SEC Form 4] [Middlekauff W Bradford was granted 69,201 shares (SEC Form 4)](https://www.quantisnow.com/insight/middlekauff-w-bradford-was-granted-69201-shares-sec-form-4-5033472)
- 2023-10-24 00:26 UTC [SEC Form 4] [Mcdade Mark was granted 348,949 shares (SEC Form 4)](https://www.quantisnow.com/insight/mcdade-mark-was-granted-348949-shares-sec-form-4-5033471)
- 2023-10-24 00:25 UTC [SEC Form 4] [Kulkarni Sandeep Chidambar was granted 716,085 shares (SEC Form 4)](https://www.quantisnow.com/insight/kulkarni-sandeep-chidambar-was-granted-716085-shares-sec-form-4-5033469)
- 2023-10-24 00:24 UTC [SEC Form 4] [Kantoff Aaron was granted 37,891 shares (SEC Form 4)](https://www.quantisnow.com/insight/kantoff-aaron-was-granted-37891-shares-sec-form-4-5033467)
- 2023-10-24 00:23 UTC [SEC Form 4] [Jones Susan Dana was granted 22,934 shares (SEC Form 4)](https://www.quantisnow.com/insight/jones-susan-dana-was-granted-22934-shares-sec-form-4-5033465)
- 2023-10-24 00:21 UTC [SEC Form 4] [Johnson Kevin Bruce was granted 57,834 shares (SEC Form 4)](https://www.quantisnow.com/insight/johnson-kevin-bruce-was-granted-57834-shares-sec-form-4-5033464)
- 2023-10-24 00:20 UTC [SEC Form 4] [Chyung Yung H. was granted 56,836 shares (SEC Form 4)](https://www.quantisnow.com/insight/chyung-yung-h-was-granted-56836-shares-sec-form-4-5033463)
- 2023-10-24 00:18 UTC [SEC Form 4] [Castelein Caley was granted 954,558 shares (SEC Form 4)](https://www.quantisnow.com/insight/castelein-caley-was-granted-954558-shares-sec-form-4-5033462)
- 2023-10-23 22:34 UTC [SEC Form 3] [SEC Form 3 filed by new insider Thiara Parvinder](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-thiara-parvinder-5033423)
- 2023-10-23 22:33 UTC [SEC Form 3] [SEC Form 3 filed by new insider Robinson Ryan F.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-robinson-ryan-f-5033420)
- 2023-10-23 22:32 UTC [SEC Form 3] [SEC Form 3 filed by new insider Middlekauff W Bradford](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-middlekauff-w-bradford-5033419)
- 2023-10-23 22:31 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kulkarni Sandeep Chidambar](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kulkarni-sandeep-chidambar-5033418)
- 2023-10-23 22:31 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kantoff Aaron](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kantoff-aaron-5033417)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TALS
- RSS and alerts for TALS: https://www.quantisnow.com/docs/rss-feeds.md